Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
JCO Turns 40.
Miller KD, Friedberg JW. Miller KD, et al. J Clin Oncol. 2023 Jan 1;41(1):1-2. doi: 10.1200/JCO.22.02480. Epub 2022 Nov 18. J Clin Oncol. 2023. PMID: 36399693 No abstract available.
Introducing Clinical Trial Updates.
Miller KD, Friedberg JW. Miller KD, et al. J Clin Oncol. 2022 May 20;40(15):1599-1600. doi: 10.1200/JCO.22.00501. Epub 2022 Apr 14. J Clin Oncol. 2022. PMID: 35420901 No abstract available.
ASCO Living Guidelines: The Next Frontier.
Giri VN, Oliver TK, Rumble RB, Friedberg JW, Miller KD, Geisel RL. Giri VN, et al. Among authors: miller kd. J Clin Oncol. 2023 Feb 10;41(5):955-957. doi: 10.1200/JCO.22.02344. Epub 2022 Dec 19. J Clin Oncol. 2023. PMID: 36534929 No abstract available.
A New Look as JCO Looks to the Future.
Miller KD, Cochran A, Gunn E, Friedberg JW. Miller KD, et al. J Clin Oncol. 2023 Jul 1;41(19):3478-3479. doi: 10.1200/JCO.23.00796. J Clin Oncol. 2023. PMID: 37379689 No abstract available.
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.
Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, Albain KS, Crivellari D, Fang L, Michelson G, de Haas SL, Burris HA. Miller KD, et al. J Clin Oncol. 2014 May 10;32(14):1437-44. doi: 10.1200/JCO.2013.52.6590. Epub 2014 Apr 14. J Clin Oncol. 2014. PMID: 24733796 Clinical Trial.
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. O'Shaughnessy J, et al. Among authors: miller kd. J Clin Oncol. 2014 Dec 1;32(34):3840-7. doi: 10.1200/JCO.2014.55.2984. Epub 2014 Oct 27. J Clin Oncol. 2014. PMID: 25349301 Clinical Trial.
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Miller KD, et al. J Clin Oncol. 2018 Sep 1;36(25):2621-2629. doi: 10.1200/JCO.2018.79.2028. Epub 2018 Jul 24. J Clin Oncol. 2018. PMID: 30040523 Free PMC article. Clinical Trial.
515 results